NSCLC Connect
  • Saved

5mo
Case Report: pembrolizumab monotherapy achieves durable disease control in a patient with BRAF V600E-mutant advanced lung adenocarcinoma and high PD-L1 expression intolerant to BRAF/ MEK inhibition - PubMed

Case Report: pembrolizumab monotherapy achieves durable disease control in a patient with BRAF V600E-mutant advanced lung adenocarcinoma and high PD-L1 expression intolerant to BRAF/ MEK inhibition - PubMed

Source : https://pubmed.ncbi.nlm.nih.gov/41777654/

Patients with advanced NSCLC and BRAF mutations who cannot tolerate targeted therapy are expected to benefit from immunotherapy.

Case report shows pembrolizumab monotherapy achieved durable disease control in advanced BRAF V600E-mutant NSCLC with high PD-L1 after intolerance to BRAF/MEK inhibitors, demonstrating immunotherapy as a viable alternative treatment.

 

  • Saved

5mo
Detection of a Rare Intra-ALK Inversion and ALK Rearrangement in a Lung Adenocarcinoma Patient by FoundationOne Liquid CDx and Successful Treatment with Alectinib: Case Report - PubMed

Detection of a Rare Intra-ALK Inversion and ALK Rearrangement in a Lung Adenocarcinoma Patient by FoundationOne Liquid CDx and Successful Treatment with Alectinib: Case Report - PubMed

Source : https://pubmed.ncbi.nlm.nih.gov/41705094/

A 50-year-old woman with stage IVB lung adenocarcinoma tested negative for driver mutations using the Oncomine Dx Target Test Multi-CDx system (Thermo Fisher Scientific, Waltham, MA). After undergoing chemotherapy and...

Case report of stage IVB lung adenocarcinoma where standard testing missed rare EML4-ALK rearrangement. FoundationOne Liquid CDx detected it, enabling alectinib therapy with rapid improvement and sustained disease control over seven months.

  • Saved

6mo
A Second Look at Refractory Edema: Delayed Diagnosis of Paraneoplastic Cushing's Syndrome in Small Cell Lung Cancer - PubMed

A Second Look at Refractory Edema: Delayed Diagnosis of Paraneoplastic Cushing's Syndrome in Small Cell Lung Cancer - PubMed

Source : https://pubmed.ncbi.nlm.nih.gov/41425668/

Paraneoplastic Cushing syndrome (PCS) is a rare manifestation of ectopic adrenocorticotropic hormone (ACTH) production, mostly associated with bronchial carcinoid and small cell lung cancer (SCLC). Its clinical manifestations: refractory hypertension,...

Case report highlights delayed diagnosis of paraneoplastic Cushing’s syndrome in small cell lung cancer, emphasizing diagnostic bias, characteristic metabolic features, and need for early suspicion to reduce morbidity and mortality.

  • Saved

6mo
A Highly Uncommon Presentation: A Consecutive Three-Case Series of Malignant Ureteral Obstruction in Long-Term Survivors of Non-small Cell Lung Cancer - PubMed

A Highly Uncommon Presentation: A Consecutive Three-Case Series of Malignant Ureteral Obstruction in Long-Term Survivors of Non-small Cell Lung Cancer - PubMed

Source : https://pubmed.ncbi.nlm.nih.gov/41635341/

Malignant ureteral obstruction (MUO) is an exceptionally rare complication in non-small cell lung cancer (NSCLC), particularly among long-term survivors. We report three cases of MUO arising in patients with stage...

Case series reports rare malignant ureteral obstruction in long-term NSCLC survivors, including EGFR-mutated cases, highlighting prolonged survival, need for early recognition, and benefits of timely ureteral decompression to preserve renal function.

  • Saved

6mo
case study

Patient Background:

A 74-year-old man presented with a three-week history of progressive headaches and mild cognitive slowing. His medical history was notable for well-controlled hypertension. Despite advanced age, his preoperative functional status was relatively preserved, with a Karnofsky Performance Status (KPS) of 80 and a Charlson Comorbidity Index (CCI) of 5.

Family history:

There was no family history of primary brain tumors or known hereditary cancer syndromes.

Assessment and Diagnosis:

Brain MRI demonstrated a contrast-enhancing right temporal lobe lesion measuring approximately 29 cm³, calculated using the ABC/2 method. Given the patient’s preserved functional status and focal disease, he underwent craniotomy with gross total resection (GTR). Postoperative MRI obtained within 72 hours confirmed complete resection. Histopathologic analysis revealed IDH–wild-type glioblastoma with an unmethylated MGMT promoter.

  1. In older adults with IDH–wild-type glioblastoma, which clinical factors support aggressive multimodal therapy?
  2. What patient- or system-level barriers most commonly limit access to GTR and adjuvant treatment in elderly patients?